Cardiometabolic Diseases Global Market Report 2024: Key Players, Demand Patterns And Forecasts 2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Cardiometabolic Diseases Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The cardiometabolic diseases market size has grown steadily in recent years. It will grow from $106.3 billion in 2023 to $110.9 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to sedentary lifestyles, urbanization and lifestyle shifts, industrialization and processed foods, genetic predispositions, environmental factors.

The cardiometabolic diseases market size is expected to see steady growth in the next few years. It will grow to $128.98 billion in 2028 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to obesity epidemic, aging population continues, healthcare infrastructure development, genomic and precision medicine, chronic stress and mental health. Major trends in the forecast period include health education and awareness, corporate wellness programs, community health programs, prevention-centric healthcare, integrated care approaches.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=11929&type=smp

Market Segmentation:
The cardiometabolic diseases market covered in this report is segmented -
1) By Type: Chronic/Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity
2) By Treatment: ACE inhibitors, Diuretics, Glucophage, Liposuction, Other Treatments
3) By Dosage: Tablet, Injection
4) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
5) By End-Users: Clinic, Hospital, Other End-Users

Major Driver - Rising Obesity Rates Fuel Growth In Cardiometabolic Disease Market
A high rate of obesity is expected to propel the growth of the cardiometabolic disease market going forward. Obesity is a complex condition characterized by the excessive accumulation of body fat, leading to higher body weight. Obesity directly influences the occurrence of cardiovascular risk factors such as dyslipidemia, type 2 diabetes, hypertension, and sleep problems. For instance, in March 2022, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, over 1 billion individuals are affected by obesity globally, which included 340 million teenagers, 650 million adults, and 39 million kids each year. By 2025, the WHO predicts that 167 million adults and children are going to lose some of their health due to being overweight or obese. Therefore, the high rate of obesity is driving the growth of the cardiometabolic diseases market.

Competitive Landscape:
Major companies operating in the cardiometabolic diseases market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Thermo Fisher Scientific, Abbott Laboratories, Takeda Pharmaceutical Company, Eli Lilly and Company, Novo Nordisk A/S, Siemens Healthineers, Boehringer Ingelheim International GmbH, Becton, Dickinson and Company, Stryker Corporation, AstraZeneca Plc, Viatris Inc., Biocrates Life Sciences AG, Boston Scientific, Astellas Pharma Inc., Terumo Corporation, Agilent Technologies, Edwards Lifesciences, Bruker Corporation, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Cardax Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Top Trend - Cardiometabolic Diseases Market Embraces Advanced Solutions
The adoption of advanced technologies is a key trend gaining popularity in the cardiometabolic diseases market. Companies involved in the market for cardiometabolic diseases are working on adopting novel technologies to sustain their position in the market. For instance, in February 2023, Eko Health Inc., a US-based inventor of heart and lung disease-detecting digital health technologies, launched the Sensora cardiac disease detection platform. It includes artificial intelligence (AI) that reliably detects structural murmurs, a symptom of valvular heart disease (VHD), and care pathway analytics software that provides metrics and downstream insight into the patient journey through the healthcare system. This digital stethoscope is used to capture and analyze electrical impulses and heartbeats.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Cardiometabolic Diseases Market Characteristics
3. Cardiometabolic Diseases Market Trends And Strategies
4. Cardiometabolic Diseases Market - Macro Economic Scenario
5. Cardiometabolic Diseases Market Size And Growth
…..
27. Cardiometabolic Diseases Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.